Journal of Medicinal Chemistry · 2002 · 33 citations · 15 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryMolecular PharmacologyNeuropharmacologyAnalgesic PharmacologyDrug-receptor InteractionsLigand BindingNeuropeptide PharmacologyPain NeurobiologyReceptor PharmacologyCompound IdentificationNeuropeptide AgonistsNociceptor ActivationNociceptor FunctionNociceptor PhysiologyPain Pharmacology
Novel hexahydrospiro[piperidine-4,1'-pyrrolo[3,4-c]pyrroles that act as potent and selective orphanin FQ/nociceptin (N/OFQ) receptor (NOP) agonists were identified. The best compound, (+)-5a, potently inhibited 3H-N/OFQ binding to the NOP receptor (K(i) = 0.49 nM) but was >1000-fold less potent in binding to MOP, KOP, and DOP opiate receptors. Further, (+)-5a potently stimulated GTP gamma S binding to NOP membranes (EC50 = 65 nM) and inhibited forskolin-mediated cAMP accumulation in NOP-expressing cells (EC50 = 9.1 nM) with a potency comparable to that of the natural peptide agonist N/OFQ. These results indicate that (+)-5a is a highly selective and potent small-molecule full agonist of the NOP receptor.
15
Orphanin FQ: A Neuropeptide That Activates an Opioidlike G Protein-Coupled Receptor
Rainer K. Reinscheid, Hans‐Peter Nothacker, Anne Bourson et al. · Science · 1995 · 1.8K citations
Medicine, Neuroscience, Pharmacology +17
ORL1, a novel member of the opioid receptor family
Catherine Mollereau, Marc Parmentier, Pierre Mailleux et al. · FEBS Letters · 1994 · 1.1K citations